October 30, 2024 | Patient Retention, clinical research, clinical trials, patient engagement, patient recruitment
Eloise Moffett, Innovative Trials’ Vice President of Commercial, reflects on how the company’s growing presence in the US is transforming client relationships and its ability to provide the best patient-centric clinical trial patient recruitment and retention solutions for the US market.

Eloise Moffett, Vice President of Commercial, reflects on Innovative Trials’ growth journey—from opening a US entity in North Carolina’s Research Triangle to strengthening relationships with US clients and launching impactful programs like the Retention Patch Program.
Read our full interview👉 https://bit.ly/4e8ySII
This content was provided by Innovative Trials
Company Details
Latest Content from Innovative Trials
See how Innovative Trials supported a Top 5 pharma to complete enrollment in a Phase 2 Lupus study
Innnovative Trials’ Equality & Diversity committee celebrates Pride Month
Discover how community engagement could enhance diversity in clinical trials patient recruitment
Innovative Trials, a global clinical trial patient recruitment and retention company based in Hertfordshire, has been recognised for its contribution to the county’s economy and business reputation.
For clinical trial participants, navigating their way through a study can sometimes seem daunting and complicated. Without the right support, around 30% are likely to drop out [1], resulting in…
Kate Shaw, Founder & CEO, comments on the Lord report of the Lord O’Shaughnessy review into commercial clinical trials in the UK.
Eloise Moffett joins Innovative Trials as New Vice President of Commercial to drive business growth globally
The news comes after a report by the Association of the British Pharmaceutical Industry (ABPI) highlighted a 44% decline in industry clinical trials in the UK over the last five…
Global clinical trials are a vital component of pharma R&D. Utilizing sites in multiple countries not only provides increased access to eligible and diverse patients – and therefore more robust…
Kate Shaw, Innovative Trials’ Founder & CEM, reflects on the exciting news for patients affected by cancer in the UK.
